LOTHIAN FORMULARY COMMITTEE
|
|
- Dorthy Carson
- 5 years ago
- Views:
Transcription
1 FORMULARY COMMITTEE Minutes of the Formulary Committee meeting held on from to 16:00 in Room 8, 5 th Floor, Waverley Gate Present: Dr Thulani Ashcroft Dr Maria Corretge Dr James Dear Neil Fontaine Carol Holmes Liz Leitch Jane Pearson Alison Rowe Laura Shaw Garry Todd Dr Lucy Wall Dr Andrew Watson General Practitioner, NHS Lothian Consultant Geriatrician, St John s Hospital, Livingston Consultant Clinical Pharmacologist, Royal Infirmary of Edinburgh Nurse Practitioner, St John s Hospital, Livingston Primary Care Pharmacist, NHS Lothian, NHS Borders Lead Pharmacist, NHS Lothian, NHS Lothian Lead Pharmacist, Royal Hospital for Sick Children (in the chair) Lead Pharmacist, Royal Edinburgh Hospital and Roodlands Hospital Consultant Medical Oncologist, Western General Hospital Consultant Psychiatrist, Royal Edinburgh Hospital Apologies for absence: Dr Jane Goddard Dr Peter Hall Dr Sara Hornibrook Dr Simon Hurding Fraser Notman Renal Consultant, Royal Infirmary of Edinburgh Consultant Medical Oncologist, Western General Hospital General Practitioner, NHS Lothian General Practitioner, NHS Lothian Prescribing Support Pharmacist, NHS Fife Membership Declarations of interest: The Chair reminded members to declare any interests in any of the products to be discussed. 1. Minutes of the previous meeting held on 18 th April In the minutes from the last meeting, item 5.4 Rapilose was listed as Additional List, for Specialist use only. This should be for General Use. Webtables will be updated with this information 2. Matters arising from previous minutes 2.1 Oncology Service implications The committee noted the statement from the Lead Cancer Care Pharmacist that all submitted formulary applications are only approved once service awareness has been considered. The applications are shared with other health boards in SCAN at the time of submission to Formulary Committee to enable them to consider service implications. 2.2 Relvar Ellipta As per April SMC advice, the licence for Relvar Ellipta has recently been extended to include use in the regular treatment of asthma in adults and adolescents aged 12 years and over where use of a combination medicinal product is appropriate for patients already adequately controlled on both inhaled corticosteroid and long acting beta2 agonist. Page 1 of 11
2 2.2.2 This change will not be assessed by SMC. The respiratory working group has been informed. 2.3 Adoport (tacrolimus) Following a Formulary Amendment Request form discussed at the last meeting, the committee agreed to add the Adoport brand of tacrolimus to the LJF The transplant unit has requested that this change does not go live until this switch is widely communicated to GPs and community pharmacists. 3. SMC Recommendations 3.1 cladribine (Mavenclad ) The committee noted and discussed the previously circulated submission and SMC report. cladribine (Mavenclad ) SMC No. 1300/18 ADVICE: following a full submission cladribine (Mavenclad ) is accepted for restricted use within NHS Scotland. Indication under review: treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features. SMC restriction: * Patients with rapidly evolving severe relapsing-remitting MS: patients with two or more relapses in the prior year whether on treatment or not, and at least one T1 gadolinium-enhancing lesion. * Patients with sub-optimal therapy relapsing-remitting MS: patients with one or more relapses in the previous year while on disease modifying therapy, and at least one T1 gadolinium-enhancing lesion or nine T2 lesions. In a phase III study cladribine showed superiority over placebo in terms of annualised relapse rate in patients with high disease activity relapsing-remitting multiple sclerosis The committee noted the treatment course consisting of one week of treatment at the start of year. The oral formulation is convenient for patients. The submitted treatment protocol is in line with SMC advice Trials have compared cladribine to placebo rather than other drugs, but the evidence is robust Expenditure on cladribine will be monitored through the Acute Prescribing Forum and MURG The committee agreed to classify cladribine (Mavenclad ) as routinely available in line with national guidance. Included on the Additional List, for Specialist Use only. Page 2 of 11
3 3.2 olaratumab (Lartruvo ) The committee noted and discussed the previously circulated submission and SMC report. olaratumab 10mg/mL concentrate for solution for infusion (Lartruvo ) SMC No. 1273/17 ADVICE: following a full submission considered under the end of life and ultra-orphan process: olaratumab (Lartruvo ) is accepted for restricted use within NHS Scotland. Indication under review: In combination with doxorubicin for the treatment of adult patients with advanced soft-tissue sarcoma who are not amenable to curative treatment with surgery or radiotherapy and who have not been previously treated with doxorubicin. SMC restriction: for use in combination with doxorubicin as first-line treatment for advanced soft-tissue sarcoma not amenable to curative treatment with surgery or radiotherapy. In an open-label phase II study, olaratumab in combination with doxorubicin improved progressionfree and overall survival compared with doxorubicin alone in patients with advanced soft-tissue sarcoma not amenable to surgery or radiotherapy. This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost effectiveness of olaratumab. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower. This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting It was noted that the incidence is 25 patients per year; the cost in the financial spreadsheet is therefore overestimated As there is no phase III data, only conditional marketing approval is in place at present. The committee agreed that patients should be informed of this It was noted that it was a good quality phase II trial that was described in the SMC advice The committee agreed to classify olaratumab (Lartruvo ) as routinely available in line with national guidance. Included on the Additional List, for Specialist Use only. 3.3 nivolumab (Opdivo ) The committee noted and discussed the previously circulated submission and SMC report. nivolumab (Opdivo ) SMC No. 1261/17 ADVICE: following a full submission assessed under the end of life and ultra-orphan medicine process: nivolumab (Opdivo ) is accepted for restricted use within NHS Scotland. Indication under review: As monotherapy, for the treatment of squamous cell cancer of the head and neck (SCCHN) in adults progressing on or after platinum-based therapy. SMC restriction: treatment with nivolumab is subject to a two year clinical stopping rule. A phase III randomised study demonstrated significantly improved overall survival in patients receiving nivolumab compared with investigator choice of treatment (taxane, folic acid antagonist or epidermal growth factor receptor monoclonal antibody) in adults with SCCHN who had progressed within six months after platinum-based therapy. This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost effectiveness of nivolumab. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower. Page 3 of 11
4 3.3.2 Selected patients fit the SMC criteria. Treatment is with a 60-minute infusion every two weeks. Patients would be treated for three months It was noted the total for SCAN is 5 patients, but the costs are based on treating 10 patients which requires clarification by the clinical team The committee agreed to classify nivolumab (Opdivo ) as routinely available in line with national guidance. Included on the Additional List, for Specialist Use only. 3.4 pembrolizumab (Keytruda ) The committee noted and discussed the previously circulated submission and SMC report. No declarations of interests were included with the application. pembrolizumab (Keytruda ) SMC No. 1291/18 ADVICE: following a full submission assessed under the end of life and orphan medicine process: pembrolizumab (Keytruda ) is accepted for restricted use within NHS Scotland. Indication under review: as monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy. SMC restriction: treatment with pembrolizumab is subject to a two-year clinical stopping rule. In a phase III study of patients with measurable urothelial carcinoma with progressive disease on or after platinum-based chemotherapy, treatment with pembrolizumab was associated with a statistically significant improvement in overall survival when compared with investigator s choice of single-agent chemotherapy. This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost effectiveness of pembrolizumab. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower. This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting The committee discussed the application and noted that the treatment options for this patient group are limited as they may not be sufficiently fit for chemotherapy. Patient numbers are estimated at per year The SMC restriction of a two-year clinical stopping rule was noted. Patient response would require to be monitored and the committee queried what would happen if duration of treatment was longer than planned. It should be used as per the SMC restriction The committee agreed to classify pembrolizumab (Keytruda ) as routinely available in line with national guidance. Included on the Additional List, for Specialist Use only. Page 4 of 11
5 3.5 eliglustat (Cerdelga ) The committee noted and discussed the previously circulated submission and SMC report. eliglustat 84mg hard capsules (Cerdelga ) SMC No. 1277/17 ADVICE: following a full submission considered under the ultra-orphan process: eliglustat (Cerdelga ) is accepted for use within NHS Scotland. Indication under review: for the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who are CYP2D6 poor metabolisers, intermediate metabolisers or extensive metabolisers. In a phase III, randomised, controlled study in patients with GD1 who were previously stabilised on enzyme replacement therapy (ERT), comparable proportions of patients treated with eliglustat versus ERT maintained stability of haemoglobin concentration, platelet count, spleen and liver volumes at a non-inferiority margin of 25% in the protocol-specified analysis. This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of eliglustat. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower. This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting Eliglustat will be funded by NHS National Services Scotland and is proposed to be provided by homecare services The convenience and advantage of a tablet formulation over an infusion was noted The committee noted the SMC advice is applicable to adults only. If paediatric services wish to use eliglustat, a FAF3 would be required The committee agreed to classify eliglustat (Cerdelga ) as routinely available in line with national guidance. Included on the Additional List, for Specialist Use only. Page 5 of 11
6 3.6 teduglutide (Revestive ) The committee noted and discussed the previously circulated submission and SMC report. teduglutide 5mg and 1.25mg vials of powder and solvent for solution for injection (Revestive ) SMC No 1139/16 ADVICE: following a full submission assessed under the ultra-orphan medicine process: teduglutide (Revestive ) is accepted for restricted use within NHS Scotland. Indication under review: for the treatment of patients aged one year and above with short bowel syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery. SMC restriction: initiation in paediatric patients (aged 1 to 17 years). Results of one phase III randomised study in adults demonstrated that significantly more patients treated with teduglutide compared with placebo achieved at least a 20% reduction in parenteral support at weeks 20 and 24. A 12-week open-label, non-randomised study in paediatric patients also found parenteral support was reduced with teduglutide compared with standard of care. This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of teduglutide. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower. This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting It was noted this is the only licensed medicine for short bowel syndrome and this medicine provides an unmet need Patient selection criteria in the FAF fit the SMC criteria The limitations with cost analysis data were noted; patient numbers are small as short bowel syndrome is rare The risks of home TPN were acknowledged. Teduglutide provides a safer alternative which is cost neutral after 77 days of TPN are avoided It was noted that treatment is lifelong and that these patients starting treatment in the paediatric service will transition to adult services The committee agreed to classify teduglutide (Revestive ) as routinely available in line with national guidance. Included on the Additional List, for Specialist Use only. Page 6 of 11
7 3.7 dimethyl fumarate (Skilarence ) The committee noted and discussed the previously circulated submission and SMC report. dimethyl fumarate 30mg and 120mg gastro-resistant tablets (Skilarence ) SMC No 1313/18 ADVICE: following a full submission: dimethyl fumarate (Skilarence ) is accepted for restricted use within NHS Scotland. Indication under review: for the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy. SMC restriction: for use in patients in whom other non-biologic systemic treatments (methotrexate, ciclosporin and acitretin) are not appropriate or have failed and who are considered unsuitable for biologic therapy given their current disease state or personal preference. In a 16 week, double-blind, phase III study, dimethyl fumarate was superior to placebo and non-inferior to a fumaric acid ester product at improving the symptoms of moderate to severe plaque psoriasis in adults The committee noted this replaces Fumaderm which is not licensed for this indication. Dimethyl fumarate has been shown to be non-inferior to Fumaderm and the incidence of side-effects is similar Dimethyl fumarate would be offered before treatment with biologic agents The committee agreed to classify dimethyl fumarate (Skilarence ) as routinely available in line with national guidance. Included on the Additional List, for Specialist Use only. 3.8 sofosbuvir 400mg, velpatasvir (Epclusa ) The committee noted and discussed the previously circulated submission and SMC report. Declaration of interest forms were included with the application and noted by the committee. sofosbuvir 400mg, velpatasvir 100mg film-coated tablets (Epclusa ) ADVICE: following a resubmission: SMC No 1271/17 sofosbuvir-velpatasvir (Epclusa ) is accepted for restricted use within NHS Scotland. Indication under review: treatment of chronic hepatitis C virus (HCV) infection in adults. SMC restriction: in patients with genotype 1 or 4 HCV infection. Sofosbuvir-velpatasvir was associated with high rates of sustained virologic suppression in adults with genotype 1 and 4 chronic HCV infection, including those with decompensated cirrhosis. This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of sofosbuvir-velpatasvir. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower The committee noted Epclusa would be used after other regimes have been tried or are considered unsuitable due to drug interactions The high percentage of adverse reactions in the trials was noted Small patient numbers are estimated by the clinical team. Page 7 of 11
8 3.8.5 National guidance is not yet published; local treatment protocol will follow these once they are available The committee agreed to classify sofosbuvir 400mg, velpatasvir (Epclusa ) as routinely available in line with national guidance. Included on the Additional List, for Specialist Use only. 3.9 sofosbuvir 400mg, velpatasvir 100mg, voxilaprevir 100mg (Vosevi ) The committee noted and discussed the previously circulated submission and SMC report. Declaration of interest forms were included with the application and noted by the committee. sofosbuvir 400mg, velpatasvir 100mg, voxilaprevir 100mg film-coated tablet (Vosevi ) SMC No 1317/18 ADVICE: following a full submission: sofosbuvir-velpatasvir-voxilaprevir (Vosevi ) is accepted for restricted use within NHS Scotland. Indication under review: Treatment of chronic hepatitis C virus (HCV) infection in adults. SMC restriction: for patients who: (1) have failed to achieve a sustained virologic response (SVR) with a direct-acting antiviral (DAA) or (2) are DAA-naïve, have genotype 3 (GT3) HCV infection, with or without cirrhosis, and are suitable for treatment with an eight-week course. Sofosbuvir-velpatasvir-voxilaprevir was associated with high rates of SVR in adults with chronic HCV who had failed to achieve a response with DAA medicines and in those who were naïve to these medicines. This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of sofosbuvir-velpatasvir-voxilaprevir. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower The committee acknowledged the lack of licensed treatment options for this patient group As for 3.8 above, national guidance and a local protocol is awaited The committee discussed the need to ensure treatment compliance and monitoring. To ensure treatment failure is not due to non-compliance The committee agreed to classify sofosbuvir 400mg, velpatasvir 100mg, voxilaprevir 100mg (Vosevi ) as routinely available in line with national guidance. Included on the Additional List, for Specialist Use only. 4. SMC latest Not Recommended Medicines 4.1 brentuximab vedotin 50mg powder for concentrate for solution for infusion (Adcetris ) SMC No is not recommended for use within NHS Scotland as monotherapy for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant. Page 8 of 11
9 4.2 naltrexone hydrochloride / bupropion hydrochloride 8mg / 90mg (Mysimba ) SMC No is not recommended for use within NHS Scotland as an adjunct to a reducedcalorie diet and increased physical activity, for the management of weight in adult patients ( 18 years) with an initial Body Mass Index (BMI) of 30 kg/m² (obese), or 27 kg/m² to < 30 kg/m² (overweight) in the presence of one or more weight-related comorbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension) 5. Other Medicines Proposed for Use 5.1 ranibizumab (Lucentis ) The committee noted the FAF3 submission for ranibizumab as treatment for advanced retinopathy of prematurity It was noted ranibizumab is already being used within the service The committee noted the reasons for wanting to use ranibizumab rather than bevacizumab No financial information was included with the application. The clinical team will be asked to submit this The committee agreed to classify ranibizumab as routinely available in line with local guidance Added to the Additional List for Specialist use only. It has been categorised RED under the ADTC Policy for the use of unlicensed (and off-label use) Medicines in NHS Lothian. Included on the Additional List, for Specialist Use only. 6. SMC Abbreviated Submissions 6.1 icatibant acetate, 30mg, solution for injection in pre-filled syringe (Firazyr ) icatibant acetate, 30mg, solution for injection in pre-filled syringe (Firazyr ) SMC No. 1332/18 ADVICE: following an abbreviated submission icatibant acetate (Firazyr ) is accepted for use within NHS Scotland. Indication under review: symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adolescents and children aged 2 years and older, with C1-esterase-inhibitor deficiency. SMC has previously accepted icatibant acetate for use in adults SMC have previously approved icatibant for use in adults (SMC 476/08) but this is not included in the LJF because clinicians did not respond to an invitation to apply for formulary inclusion If paediatric services wish to use icatibant acetate, a FAF1 would be required. The clinical team will be advised. It would be preferable for the FAF1 to incorporate adult and paediatric patient populations The committee agreed to classify icatibant acetate (Firazyr ) as Not Routinely available as local clinical experts do not wish to add the medicine to the formulary at this time. Page 9 of 11
10 7. Non-submissions to Formulary Committee (90-day target) 7.1 sarilumab (Kevzara ) SMC No 1314/ The clinical team have advised that a submission will be made and are aiming for the next Formulary Committee meeting Not routinely available as local implementation plans are being developed or the ADTC is waiting for further advice from local clinical experts - decision expected by July Formulary Additions and Amendments 8.1 Formulary additions prednisolone SBAR An SBAR was presented discussing options for oral prednisolone formulations when patients cannot swallow tablets. Soluble tablets are now more cost effective than liquid in primary care only. The standard prednisolone tablets remain the most cost effective option when a patient is able to swallow The committee agreed to add prednisolone soluble 5mg tablets to the LJF. This will provide flexibility for prescribers and patients in selecting the most appropriate formulation The LJF will be updated. An article will be included in the Lothian Prescribing Bulletin to highlight the change. 8.2 Formulary amendment request forms None 9. NICE/SIGN/HIS Clinical Guidance 9.1 TA517 Avelumab for treating metastatic Merkel cell carcinoma (for info) TA518Tocilizumab for treating giant cell arteritis (for info) TA519 Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (for info) or-metastatic-urothelial-carcinoma-after-platinumcontaining-chemotherapy-pdf SIGN 151 Management of stable angina April 2018, full guideline The committee noted that further detail may be needed in the LJF section regarding course lengths of aspirin and clopidogrel in patients with stents. The working group will be contacted to review the current LJF advice. 10. Drug Safety Issues MHRA Advice 10.1 Drug Safety Update Volume 11, Issue 9 (April 2018) The committee noted valproate medicines are contraindicated in women and girls of childbearing potential unless conditions of the Pregnancy Prevention Programme are met. Page 10 of 11
11 This follows an EU-wide review into the significant harms from use of valproate medicines in pregnancy Amendments to relevant LJF sections advising of the new measures are being sent to all relevant working groups for approval. The updates will not be required to be approved by Formulary Committee before the LJF is updated The LJF will be updated. 11. Single National Formulary 11.1 The committee noted the invite to attend the next ADTC meeting to hear the presentation on the work of the SNF. 12. For Information Only 12.1 Formulary Committee Reports and Letters: The committee noted the following Formulary Committee reports and letters: adrenaline (Emerade ) Calci-D and Accrete D3 adalimumab (Humira ) venetoclax (Venclyxto ) daratumumab (Darzalex ) nivolumab (Opdivo ) tofacitinib (Xeljanz ) adalimumab (Humira ) dexamethasone intraviteal implant aviptadil phentolamine mesilate (Invicorp ) levenorgestrel (Kyleena ) rituximab thiopenta carmustine R-DA-EPOCH Rapilose celecoxib fluticasone furoate, umeclidinium, vilanterol (Trelegy Ellipta ) lacosamide (Vimpat ) lopinavir, ritonavir (Kaletra ) sevelamer carbonate (Renvela ) recombinant E.coli asparaginase (Spectrila ) ciprofloxacin (Cetralax ) 5aminolaevulinic acid (Ameluz ) pembrolizumab (Keytruda ) ribociclib (Kisqali ) Keya tacrolimus (Adoport ) dorzolamide (Eydelto ) dorzolamide timolol (Eylamdo ) povidone iodine minims 5% 13. AOCB None 14. Date of Next Meeting Wednesday 4 th July 2018, 2.00pm, Meeting Room 8, Waverley Gate. (Please note submission date for papers is Tuesday 19 th June 2018). Apologies are to be sent to the prior to the submission deadline. Page 11 of 11
LOTHIAN FORMULARY COMMITTEE FORMULARY COMMITTEE
FORMULARY COMMITTEE Minutes of the Formulary Committee meeting held on from 14:15 in Room (6+7), 5 th Floor, Waverley Gate Present: Dr Thulani Ashcroft General Practitioner, NHS Lothian (arrived 14:45)
More informationLOTHIAN FORMULARY COMMITTEE
FORMULARY COMMITTEE Minutes of the Formulary Committee meeting held on from 14.10 to 16.15 in Room (6+7), 5 th Floor, Waverley Gate Present: Dr Thulani Ashcroft General Practitioner, NHS Lothian (arrived
More informationMedicine Condition being treated NHSGGC Decision Date of decision. 18 June 2018 Page 1 of 5
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available in a health board only after it has been: accepted for use in by the Scottish Medicines
More informationArea Drug and Therapeutics Committee Prescribing Supplement No 55 March 2012
Area Drug and Therapeutics Committee Prescribing Supplement No 55 In this issue Drugs reviewed by the SMC in February 2012 ADTC UPDATES ON DRUGS REVIEWED BY THE SMC The following new drugs have been reviewed
More informationLOTHIAN FORMULARY COMMITTEE FORMULARY COMMITTEE
FORMULARY COMMITTEE Minutes of the Formulary Committee meeting held on from 14.00 16.45 in Room 004, Ground Floor, Pentland House Present: Krista Clubb Nurse Prescribing Coordinator, NHS Lothian Dr Maria
More informationPROTECTIVE MARKING: NONE NHS GRAMPIAN Minute of Formulary Group Meeting Tuesday 20 March 2018 at 14:30 in the Seminar Room, David Anderson Building
NHS GRAMPIAN Minute of Formulary Group Meeting Tuesday 20 March 2018 at 14:30 in the Seminar Room, David Anderson Building PRESENT APOLOGIES APPROVED Ms A Davie Dr D Counter Ms F Doney Dr D Culligan Dr
More informationArea Drug and Therapeutics Committee Prescribing Supplement No 59 July 2012
Area Drug and Therapeutics Committee Prescribing Supplement No 59 In this issue Drugs reviewed by the SMC in June 2012 ADTC UPDATES ON DRUGS REVIEWED BY THE SMC The following new drugs have been reviewed
More informationLOTHIAN FORMULARY COMMITTEE FORMULARY COMMITTEE
FORMULARY COMMITTEE Minutes of the Formulary Committee meeting held on from 14.00 15.40 in Room 004, Ground Floor, Pentland House Present: Krista Clubb Nurse Prescribing Coordinator, NHS Lothian Dr Maria
More informationDrugs reviewed by the SMC in September 2012 ADTC UPDATES ON DRUGS REVIEWED BY THE SMC
Area Drug and Therapeutics Committee Prescribing Supplement No 62 In this issue Drugs reviewed by the SMC in September 2012 ADTC UPDATES ON DRUGS REVIEWED BY THE SMC The following new drugs have been reviewed
More informationNHS GRAMPIAN Minute of Formulary Group Meeting Tuesday 17 July 2018 at 14:30 in the Seminar Room, David Anderson Building PRESENT APOLOGIES APPROVED
NHS GRAMPIAN Minute of Formulary Group Meeting Tuesday 17 July 2018 at 14:30 in the Seminar Room, David Anderson Building PRESENT APOLOGIES APPROVED Ms A Davie Dr L Elliot Ms F Doney Dr J Fitton Mrs L
More information04 September 2017 Page 1 of 6
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available in a health board only after it has been: accepted for use in by the Scottish Medicines
More informationLOTHIAN FORMULARY COMMITTEE FORMULARY COMMITTEE
FORMULARY COMMITTEE Minutes of the Formulary Committee meeting held on from 14.00 15.50 in Room 004, Ground Floor, Pentland House Present: Clare Andrews Clinical Pharmacist, Western General Hospital Krista
More informationLOTHIAN FORMULARY COMMITTEE FORMULARY COMMITTEE
FORMULARY COMMITTEE Minutes of the Formulary Committee meeting held on from 14.00 16.00 in Room 004, Ground Floor, Pentland House Present: A Gilchrist Dr SC Hornibrook Dr S Hurding L Leitch F McIntyre
More information29 August 2016 Page 1 of 7. How does the NHS board decide which new medicines to make available for patients?
NHS Greater Glasgow and Clyde: New Medicines Decisions In Scotland, a newly licensed medicine is routinely available for use in an NHS board only after it has been: accepted for use in the NHSScotland
More informationArea Drug and Therapeutics Committee Prescribing Supplement No 47 July 2011
Area Drug and Therapeutics Committee Prescribing Supplement No 47 In this issue Drugs reviewed by in May / June 2011 ADTC UPDATES ON DRUGS REVIEWED BY THE SMC The following new drugs have been reviewed
More informationLOTHIAN FORMULARY COMMITTEE FORMULARY COMMITTEE
FORMULARY COMMITTEE Minutes of the Formulary Committee meeting held on 25 th January 2012 in Board Room, Royal Victoria Hospital Present: Dr E Brown Consultant Oncologist, Western General Hospital J Carson
More informationADTC UPDATES ON DRUGS REVIEWED BY THE SMC. The following new drugs have been reviewed by the Scottish Medicines Consortium in July 2013: -
Area Drug and Therapeutics Committee Prescribing Supplement No 72 In this issue Drugs reviewed by the SMC in July 2013 ADTC UPDATES ON DRUGS REVIEWED BY THE SMC The following new drugs have been reviewed
More informationArea Drug and Therapeutics Committee Prescribing Supplement No 31 - June 2009
Area Drug and Therapeutics Committee Prescribing Supplement No 31 - In this issue Drugs currently being considered by SMC advice due on 13 th July 2009 Drug Safety Update STOP PRESS Clopidogrel and PPIs
More informationMEETING OF THE BORDERS FORMULARY COMMITTEE HELD ON WEDNESDAY 14 th FEBRUARY P.M. IN THE ESTATES MEETING ROOM MINUTE
MEETING OF THE BORDERS FORMULARY COMMITTEE HELD ON WEDNESDAY 14 th FEBRUARY 2018 @ 12.30 P.M. IN THE ESTATES MEETING ROOM MINUTE In attendance: Alison Wilson (Director of Pharmacy & Chair of BFC); Liz
More informationArea Drug and Therapeutics Committee Prescribing Supplement No 3 November 2003
Area Drug and Therapeutics Committee Prescribing Supplement No 3 In this issue Drugs currently being considered by the SMC advice due on 8 December 2003. SMC Notice of meeting: Patient power Making a Difference,
More informationPegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine TA440
This spreadsheet is updated monthly and enables self-audit of a medicines for All guidelines refer to adults unless indicated. No copyright is asserted on this Technology appraisal (TA) Titles are hyperlinks
More informationMEETING OF THE BORDERS FORMULARY COMMITTEE HELD ON WEDNESDAY 8 th FEBRUARY P.M. IN THE ESTATES MEETING ROOM MINUTE
MEETING OF THE BORDERS FORMULARY COMMITTEE HELD ON WEDNESDAY 8 th FEBRUARY 2017 @ 12.30 P.M. IN THE ESTATES MEETING ROOM MINUTE In attendance: Alison Wilson (Director of Pharmacy & Chair of BFC); Liz Leitch
More information10 Musculoskeletal and Joint Diseases
Recommendations from the Lothian Formulary Committee (FC) following Scottish Medicines Consortium (SMC) advice, NICE MTA advice, (FAF3) unlicensed and off-label medicines and (FAF2) medicines not considered
More informationArea Drug and Therapeutics Committee Prescribing Supplement No 24 August 2008
Area Drug and Therapeutics Committee Prescribing Supplement No 24 In this issue Drugs currently being considered by SMC advice due on 08 September New drug decisions relevant to Primary Care practitioners
More informationNEW MEDICINE APPLICATIONS BROUGHT TO THE BORDERS FORMULARY COMMITTEE (BFC) AND AREA DRUG & THERAPEUTICS COMMITTEE (ADTC) 2018/19
NEW MEDICINE APPLICATIONS BROUGHT TO THE BORDERS FORMULARY COMMITTEE (BFC) AND AREA DRUG & THERAPEUTICS COMMITTEE (ADTC) 2018/19 New Medicine Product/Device Endorsement Categories A B C D E F Approved
More informationResource impact report: Sofosbuvir velpatasvir for treating chronic hepatitis C TA430
Putting NICE guidance into practice Resource impact report: Sofosbuvir velpatasvir for treating chronic hepatitis C TA430 Published: January 2017 Summary Sofosbuvir velpatasvir is recommended as an option
More informationSummary of Main Points from the Meeting held on Monday 12 th December 2016
Summary of Main Points from the Meeting held on Monday 12 th December 2016 2. Minutes and Summary Notes from last meeting The Minutes and Summary notes from the November 2016 Medicines Group meeting were
More informationMEETING OF THE BORDERS FORMULARY COMMITTEE HELD ON WEDNESDAY, 8 TH AUGUST P.M. IN THE COMMITTEE ROOM, EDUCATION CENTRE
MEETING OF THE BORDERS FORMULARY COMMITTEE HELD ON WEDNESDAY, 8 TH AUGUST 2012 @ 12.30 P.M. IN THE COMMITTEE ROOM, EDUCATION CENTRE MINUTE Present: Alison Wilson (Chair), Ros Anderson (RA), Declan Hegarty
More informationLOTHIAN FORMULARY COMMITTEE FORMULARY COMMITTEE
FORMULARY COMMITTEE Minutes of the Formulary Committee meeting held on 15 December 2010 in Room 004, Ground Floor, Pentland House Present: Dr E Brown J Carson Dr J Forbes Dr H Gillett Dr S C Hornibrook
More informationNICE TECHNOLOGY APPRAISAL MEDICINES REPORT 2017
NICE TECHNOLOGY PPRISL MEDICINES REPORT St George s Healthcare NHS Trust key for medicine-related NICE Technology ppraisals. has been approved by the Drugs and Therapeutics Committee as recommended within
More informationTechnology appraisal guidance Published: 21 February 2018 nice.org.uk/guidance/ta507
Sofosbuvir velpatasvir voxilaprevir for treating chronic hepatitis C Technology appraisal guidance Published: 21 February 2018 nice.org.uk/guidance/ta507 NICE 2018. All rights reserved. Subject to Notice
More informationLANARKSHIRE AREA DRUG & THERAPEUTICS COMMITTEE. 2014/116 Apologies Mr John Milne, Mrs Victoria Mackinnon, Mr Smith Mr George Lindsay
LANARKSHIRE AREA DRUG & THERAPEUTICS COMMITTEE Minute of the meeting held on Wednesday 17 th September 2014 at 10am in the Boardroom, NHS Lanarkshire HQ, Kirklands, Bothwell PRESENT: Dr Mehrdad Malekian
More informationBORDERS FORMULARY COMMITTEE. Minutes of a Meeting held on Wednesday, 13 th April 2011 At p.m. in Discussion Room 1, Education Centre
BORDERS FORMULARY COMMITTEE Minutes of a Meeting held on Wednesday, 13 th April 2011 At 12.00 p.m. in Discussion Room 1, Education Centre Present: Alison Wilson (Chair) (AW), Declan Hegarty (DH), Ros Anderson
More informationSummary of Main Points from the Meeting held on Monday 11 th September 2017
Summary of Main Points from the Meeting held on Monday 11 th September 2017 2. Minutes and Summary Notes from last meeting The Minutes and Summary notes from the July 2017 Medicines Group meeting were
More informationdimethyl fumarate 30mg and 120mg gastro-resistant tablets (Skilarence ) SMC No 1313/18 Almirall Limited
dimethyl fumarate 30mg and 120mg gastro-resistant tablets (Skilarence ) SMC No 1313/18 Almirall Limited 9 March 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationArea Drug and Therapeutics Committee Prescribing Supplement No 32 August 2009
Area Drug and Therapeutics Committee Prescribing Supplement No 32 In this issue Drugs currently being considered by SMC advice due on 7 th September 2009 Drug safety update unlicensed and off-label prescribing
More informationLOTHIAN FORMULARY COMMITTEE FORMULARY COMMITTEE
FORMULARY COMMITTEE Minutes of the Formulary Committee meeting held on 26 th February 2014 from 2.00pm 4.30pm in Room 004, Ground Floor, Pentland House Present: Dr E Brown K Davidson V Hailey Dr SC Hornibrook
More informationMINUTES MEETING OF THE BORDERS FORMULARY COMMITTEE HELD ON WEDNESDAY, P.M. IN THE ESTATES MEETING ROOM
MINUTES MEETING OF THE BORDERS FORMULARY COMMITTEE HELD ON WEDNESDAY, 11/06/2014 @ 12.30 P.M. IN THE ESTATES MEETING ROOM Attendees: Alan Brown (minutes), Liz Leitch, Alison Wilson, Paul Neary, Ros Anderson,
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement Until 3/2/19. Nivolumab (Intravenous)
Nivolumab (Intravenous) NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3734-XX Opdivo 240
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic Agents Original Policy Date: January 16, 2015 Subject: Opdivo Page:
More informationDrugs Not Approved By the Scottish Medicines Consortium
January 2017 Vol. 14 No. 1 Outlined below in this newsletter are the recommendations for new drugs which have been through the ly agreed process (see appendix I). Please remember that the ADTC advises
More informationLOTHIAN FORMULARY COMMITTEE FORMULARY COMMITTEE
FORMULARY COMMITTEE Minutes of the Formulary Committee meeting held on 30 th January 2013 from 2.00pm 4.00pm in Room 004, Ground Floor, Pentland House Present: J Carson Lead Directorate Pharmacist, Royal
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: ERX.SPA.302 Effective Date:
Clinical Policy: (Opdivo) Reference Number: ERX.SPA.302 Effective Date: 03.01.19 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationPolicy. Medical Policy Manual Approved Revised: Do Not Implement until 6/30/2019. Nivolumab
Medical Manual Approved Revised: Do Not Implement until 6/30/2019 Nivolumab NDC CODE(S) 00003-3772-XX Opdivo 40 MG/4ML SOLN (B-M SQUIBB U.S. (PRIMARY CARE)) 00003-3774-XX Opdivo 100 MG/10ML SOLN (B-M SQUIBB
More informationNational Clinical Guidelines for the treatment of HCV in adults. Version 3
National Clinical Guidelines for the treatment of HCV in adults Version 3 January 2017 Sponsors and Authorship The guidelines have been authored on behalf of the viral hepatitis clinical leads and MCN
More informationNational Clinical Guidelines for the treatment of HCV in adults. Version 4
National Clinical Guidelines for the treatment of HCV in adults Version 4 November 2017 Sponsors and Authorship The guidelines have been authored on behalf of the viral hepatitis clinical leads and MCN
More informationLOTHIAN FORMULARY COMMITTEE FORMULARY COMMITTEE
FORMULARY COMMITTEE Minutes of the Formulary Committee meeting held on from 14.00 16.35 in Room 004, Ground Floor, Pentland House Present: Clare Andrews Clinical Pharmacist, Western General Hospital Dr
More informationA Guide to the Scottish Medicines Consortium
A Guide to the Scottish Medicines Consortium Providing advice about newly licensed medicines www.scottishmedicines.org About the Scottish Medicines Consortium The Scottish Medicines Consortium (SMC) provides
More informationChapter 8 Malignant Disease and Immunosuppression
Chapter 8 page number 1 Chapter 8 Malignant Disease and Immunosuppression First line drugs Drugs recommended in both primary and secondary care Second line drugs Alternatives (often in specific conditions)
More informationSummary of Main Points from the Meeting held on Monday 13 th March 2017
Summary of Main Points from the Meeting held on Monday 13 th March 2017 2. Minutes and Summary Notes from last meeting The Minutes and Summary notes from the February 2017 Medicines Group meeting were
More informationLOTHIAN FORMULARY COMMITTEE FORMULARY COMMITTEE
FORMULARY COMMITTEE Minutes of the Formulary Committee meeting held on 29 September 2010 in Room 004, Ground Floor, Pentland House Present: J Carson Dr J Dear Dr J Forbes Dr H Gillett Dr W Jamieson S Kerr
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: November 14, 2018 Effective Date: January 1, 2019 This drug class prior authorization criteria have been
More informationNational Clinical Guidelines for the treatment of HCV in adults. Version 5
National Clinical Guidelines for the treatment of HCV in adults Version 5 June 2018 Sponsors and Authorship The guidelines have been authored on behalf of the viral hepatitis clinical leads and MCN co-ordinators
More informationNHS GRAMPIAN Minute of Formulary Group Meeting Tuesday 21 August 2018 at 14:30 in the Seminar Room, David Anderson Building PRESENT APOLOGIES APPROVED
NHS GRAMPIAN Minute of Formulary Group Meeting Tuesday 21 August 2018 at 14:30 in the Seminar Room, David Anderson Building PRESENT APOLOGIES APPROVED Dr D Culligan (from item 8.4) Dr A MacDonald Ms A
More informationArea Drug and Therapeutics Committee Prescribing Supplement No 16 May 2007
Area Drug and Therapeutics Committee Prescribing Supplement No 16 In this issue Drugs currently being considered by the SMC advice due on 11 June 07. Correction to the last edition (No 15) of the prescribing
More informationScottish Medicines Consortium
Scottish Medicines Consortium cetuximab 2mg/ml intravenous infusion (Erbitux ) (279/06) MerckKGaA No 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationDocument Details. Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml
Title Document Details Patient Group Direction (PGD) Ibuprofen 200mg tablets and Ibuprofen oral liquid 100mg in 5ml Trust Ref No 1445-36348 Local Ref (optional) Main points the document The treatment of
More informationLocal Natalizumab Treatment Protocol
Local Natalizumab Treatment Protocol 1. New medicine name: Natalizumab 300mg concentrate for solution for infusion (Natalizumab ) 2. Licensed indication(s): Natalizumab is indicated for single disease
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic nts Original Policy Date: January 16, 2015 Subject: Opdivo Page: 1 of
More informationMeeting of the Borders Area Drugs and Therapeutics Committee was held on Wednesday, 11 th July 2012 at p.m. in the Estates Meeting Room.
Meeting of the Borders Area Drugs and Therapeutics Committee was held on Wednesday, 11 th July 2012 at 12.30 p.m. in the Estates Meeting Room. MINUTE Present: John Hammond (JH) (Chair), Alison Wilson (AW),
More informationLincolnshire Prescribing and Clinical Effectiveness Bulletin
S Lincolnshire Prescribing and Clinical Effectiveness Bulletin Volume 11 No 13, October 2017 Optum in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services,
More informationOpdivo (nivolumab) An overview of Opdivo and why it is authorised in the EU. What is Opdivo and what is it used for?
EMA/852560/2018 EMEA/H/C/003985 An overview of Opdivo and why it is authorised in the EU What is Opdivo and what is it used for? Opdivo is a cancer medicine used to treat the following: melanoma, a type
More informationNHS GRAMPIAN Minute of Formulary Group Meeting Tuesday 18 December 2018 at 14:30 in the Seminar Room, David Anderson Building
NHS GRAMPIAN Minute of Formulary Group Meeting Tuesday 18 December 2018 at 14:30 in the Seminar Room, David Anderson Building PRESENT APOLOGIES APPROVED Ms A Davie Dr D Culligan Ms F Doney Mr C Rore Dr
More informationScottish Medicines Consortium
Scottish Medicines Consortium pegylated interferon α 2b (ViraferonPeg ), 50, 80, 100, 120 or 150 micrograms powder for solution for injection in pre-filled pen, in combination with ribavirin (Rebetol ),
More informationSHARED CARE AGREEMENT: MELATONIN (CHILDREN)
NB: This document should be read in conjunction with the current Summary of Product Characteristics (SPC) where appropriate. DRUG AND INDICATION: Generic drug name: Formulations: MELATONIN 3mg immediate
More informationAbout the National Centre for Pharmacoeconomics
Cost effectiveness of sofosbuvir (in combination with either ribavirin or pegylated interferon + ribavirin) (Sovaldi ) for the treatment of hepatitis C infection The NCPE has issued a recommendation regarding
More informationLOTHIAN FORMULARY COMMITTEE FORMULARY COMMITTEE
FORMULARY COMMITTEE Minutes of the Formulary Committee meeting held on 02 March 2011 in Room 004, Ground Floor, Pentland House Present: Dr E Brown J Carson Dr J Dear Dr J Forbes Dr S C Hornibrook Professor
More informationLincolnshire Prescribing and Clinical Effectiveness Bulletin
S Lincolnshire Prescribing and Clinical Effectiveness Bulletin Volume 11 No 12, September 2017 Optum in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services,
More informationArea Drug and Therapeutics Committee Prescribing
Area Drug and Therapeutics Committee Prescribing Supplement No 103 In this issue Drugs reviewed by the SMC in March 2016 ADTC UPDATES ON DRUGS REVIEWED BY THE SMC The following new drugs have been reviewed
More informationResubmission. Scottish Medicines Consortium
Scottish Medicines Consortium Resubmission aripiprazole 5mg, 10mg, 15mg, 0mg tablets; 10mg, 15mg orodispersible tablets; 1mg/mL oral solution (Abilify ) No. (498/08) Bristol-Myers Squibb Pharmaceuticals
More informationTHEOPHYLLINE WITH INHALED CORTICOSTEROIDS (TWICS) TRIAL SELF MANAGMENT / ACTION PLANS GENUAIR INHALERS: POTENTIAL SAFETY ISSUE
I S S U E 4 M A R C H / A R P I L 2 0 1 6 Endorsed December 2014 I N S I D E T H I S I S S U E : Theophylline with Inhaled Corticosteroids (TWICS) Trial Genuair Inhaler: Potential Safety Issue 1 Self Management
More informationEvidence review for Surrey Prescribing Clinical Network SUMMARY
East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG, Surrey Heath CCG, Crawley CCG, Horsham & Mid-Sussex CCG Evidence review for Surrey Prescribing Clinical Network Medicine
More information1 st Appraisal Committee meeting Background & Clinical Effectiveness Gillian Ells & Malcolm Oswald 24/11/2016
Lead team presentation Nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy [ID971] 1 st Appraisal Committee meeting Background
More informationClinical Policy: Topotecan (Hycamtin) Reference Number: CP.PHAR.64 Effective Date: Last Review Date: Line of Business: Medicaid, HIM
Clinical Policy: (Hycamtin) Reference Number: CP.PHAR.64 Effective Date: 06.01.11 Last Review Date: 05.18 Line of Business: Medicaid, HIM Coding Implications Revision Log See Important Reminder at the
More informationentecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd
entecavir, 0.5mg and 1mg film-coated tablets and 0.05 mg/ml oral solution, Baraclude SMC No. (747/11) Bristol-Myers Squibb Pharmaceuticals Ltd 09 December 2011 The Scottish Medicines Consortium (SMC) has
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.HNMC.27 Effective Date: Last Review Date: Line of Business: Medicaid - HNMC
Clinical Policy: (Opdivo) Reference Number: CP.HNMC.27 Effective Date: 07.01.17 Last Review Date: 02.18 Line of Business: Medicaid - HNMC Revision Log See Important Reminder at the end of this policy for
More informationArea Drug and Therapeutics Committee Prescribing Supplement No 20 December 2007
Area Drug and Therapeutics Committee Prescribing Supplement No 20 In this issue Drugs currently being considered by SMC advice due on 14 January 2008. Lanarkshire Joint Formulary 2 nd edition November
More informationDescription of Commitment
AbbVie U.S. Postmarketing s Table: Name of ANDROGEL (testosterone gel) CREON (pancrelipase) CREON (pancrelipase) / 022309 and 021015 20725 20725 125057/0 125057/114 Description of A randomized, double-blind,
More informationScottish Medicines Consortium
Scottish Medicines Consortium lenalidomide, 5mg,10mg,15mg and 25mg capsules (Revlimid) No. (441/08) Celgene Europe Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment of
More informationLOTHIAN FORMULARY COMMITTEE FORMULARY COMMITTEE
FORMULARY COMMITTEE Minutes of the Formulary Committee meeting held on from 14.00 17.10 in Room 021, Ground Floor, Pentland House Present: Dr M Corretge Dr S Hurding Dr W Jamieson S Kerr L Leitch I Mohammed
More informationScottish Medicines Consortium
P Oral) Scottish Medicines Consortium vinorelbine 20 and 30mg capsules (NavelbineP Pierre Fabre Ltd No. (179/05) 06 May 2005 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationBLA /S-048, S-049, S-050, S-051, S-052, S-061, S-062, S-064, S-065, and S-066 SUPPLEMENT APPROVAL
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 BLA 125554/S-048, S-049, S-050, S-051, S-052, S-061, S-062, S-064, S-065, and S-066 SUPPLEMENT APPROVAL Bristol-Myers
More informationPatient and Public Reference Group for Medicines ADTC Sub-group NHS Tayside 17 th February 2015
Patient and Public Reference Group for Medicines ADTC Sub-group NHS Tayside 17 th February 2015 Claire James, Senior Pharmacist Clinical Effectiveness, Ninewells Hospital Aims To increase awareness and
More informationlevetiracetam 250,500,750 and 1000mg tablets and levetiracetam oral solution 100mg/1ml (Keppra ) (No. 397/07) UCB Pharma Ltd
Scottish Medicines Consortium Resubmission levetiracetam 250,500,750 and 1000mg tablets and levetiracetam oral solution 100mg/1ml (Keppra ) (No. 397/07) UCB Pharma Ltd 11 January 2008 The Scottish Medicines
More informationScottish Medicines Consortium
Scottish Medicines Consortium rituximab 10mg/ml concentrate for infusion (MabThera ) Roche (No.330/06) 10 November 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationFormulary and Prescribing Guidelines
Formulary and Prescribing Guidelines SECTION 3: TREATMENT OF BIPOLAR AFFECTIVE DISORDER This section provides information regarding the pharmacological management of Bipolar affective disorder in secondary
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
Recognising and managing bipolar disorder in adults in primary care bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are
More informationEAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD IN SEMINAR ROOM 7, LEARNING & DEVELOPMENT CENTRE, ROYAL BLACKBURN HOSPITAL
EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD MINUTES OF THE MEETING HELD ON WEDNESDAY 15 th FEBRUARY 2017 AT 12.30pm IN SEMINAR ROOM 7, LEARNING & DEVELOPMENT CENTRE, ROYAL BLACKBURN HOSPITAL
More informationVolume 11; Number 5 February 2017 REVIEW OF GONADOTROPIN RELEASING HORMONE AGONISTS FOR PROSTATE CANCER (REVISED EDITION)
Optum in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services, United Lincolnshire Hospitals Trust and Lincolnshire Partnership Foundation Trust Volume 11;
More informationLincolnshire Prescribing and Clinical Effectiveness Bulletin
S Lincolnshire Prescribing and Clinical Effectiveness Bulletin Volume 12 No 10, November 2018 Optum in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services,
More informationApril May For adults for the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion.
April May 2014 Recommended for use within NHS Scotland April May 2014 aflibercept intravitreal (Eylea ) 954/14 For adults for the treatment of visual impairment due to macular oedema secondary to central
More informationdiclofenac, 75mg/2ml of solution for intravenous injection (Dyloject ) No. (446/08) Javelin Pharmaceuticals UK Ltd
Scottish Medicines Consortium diclofenac, 75mg/2ml of solution for intravenous injection (Dyloject ) No. (446/08) Javelin Pharmaceuticals UK Ltd 11 February 2008 The Scottish Medicines Consortium has completed
More informationTechnology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364
Daclatasvir for treating chronic hepatitis C Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationSummary of Main Points from the Meeting held on Monday 9 th April 2018
Summary of Main Points from the Meeting held on Monday 9 th April 2018 2. Minutes and Summary Notes from last meeting The Minutes and Summary notes from the 12 th March 2018 Medicines Group meeting were
More informationTechnology appraisal guidance Published: 30 August 2017 nice.org.uk/guidance/ta472
Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab Technology appraisal guidance Published: 30 August 2017 nice.org.uk/guidance/ta472 NICE 2018. All rights reserved.
More informationLOTHIAN FORMULARY COMMITTEE FORMULARY COMMITTEE
FORMULARY COMMITTEE Minutes of the Formulary Committee meeting held on 11 th November 2015 from 2.00pm 5.10pm in Room 004, Ground Floor, Pentland House Present: Dr M Corretge Consultant Geriatrician, St
More informationSASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary
April 1, 2017 Bulletin #165 ISSN 1923-0761 SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary Related Information for Prescribers: Only prescribers who have completed
More informationTechnology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta493
Cladribine tablets for treating relapsing remitting multiple sclerosis Technology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta493 NICE 2018. All rights reserved. Subject to Notice
More informationMinutes of the SMC Meeting held on Tuesday 7 August 2018 DoubleTree by Hilton Hotel Glasgow Central, Cambridge Street, Glasgow, G2 3HN
Minutes of the SMC Meeting held on Tuesday 7 August 2018 DoubleTree by Hilton Hotel Glasgow Central, Cambridge Street, Glasgow, G2 3HN Present: Observers: In Attendance: Apologies: Dr Alan MacDonald (Chairman)
More information